Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents,
including radioisotopes and toxic drugs (ineffective when administered systemically alone) …

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …

Noninvasive molecular imaging approaches include nuclear, optical, magnetic resonance
imaging, computed tomography, ultrasound, and photoacoustic imaging, which require …

A great deal of effort has been made over the years to develop liposomes that have targeting
vectors (oligosaccharides, peptides, proteins and vitamins) attached to the bilayer surface …

Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …

Bispecific antibodies capable of redirecting the lytic potential of immune effector cells to kill
tumor targets have long been recognized as a potentially potent biological therapeutic …

Antibodies have long been recognised as potent vectors for carrying diagnostic medical
radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of …

Fluorescence imaging is an emerging technology that can provide real-time information
about the operating field during cancer surgery. Non-specific fluorescent agents, used for …